Kamada Ltd. Reports Strong Q1 2025 Performance with Double-Digit Growth and Strategic Milestones

Kamada Ltd. (NASDAQ: KMDA) has demonstrated robust financial health in the first quarter of 2025, with revenue climbing to $44.0 million, a 17% increase from the previous year. This growth is attributed to the company's diverse portfolio, including products like GLASSIA®, KAMRAB®, and VARIZIG®, which have seen increased demand in non-U.S. markets. The company's adjusted EBITDA also saw a significant rise of 54%, reaching $11.6 million, underscoring Kamada's operational efficiency and profitable growth trajectory.

The first quarter of 2025 was marked by several strategic achievements for Kamada, including the launch of a post-marketing research program for CYTOGAM®, aimed at enhancing CMV disease management. This initiative reflects Kamada's commitment to advancing medical research and improving patient outcomes in high-risk populations. Additionally, the expansion of Kamada's plasma collection capabilities with a new center in San Antonio, Texas, signifies a strategic move to secure raw material supply and reduce dependency on third-party suppliers, potentially adding $8 million to $10 million in annual revenue at full capacity.

Kamada's forward-looking statements reiterate confidence in its growth strategy, with expected total revenue between $178 million and $182 million and adjusted EBITDA of $38 million to $42 million for 2025. These projections highlight the company's optimism in its organic growth, business development initiatives, and the advancement of its Inhaled AAT program. The company's ability to secure a $25 million deal for KAMRAB and VARIZIG in Latin America further exemplifies its global expansion and commercial success.

The implications of Kamada's Q1 performance and strategic milestones are significant for the biopharmaceutical industry, investors, and patients alike. For the industry, Kamada's growth and expansion into plasma collection underscore the importance of vertical integration and innovation in driving profitability. Investors may view Kamada's consistent performance and strategic initiatives as indicators of long-term value creation. For patients, Kamada's advancements in treatments for conditions like AAT deficiency and CMV disease represent hope for improved therapeutic options and outcomes. Kamada's Q1 2025 results not only reflect its current success but also its potential to shape the future of biopharmaceutical solutions.